Demyelinating and thrombotic diseases of the central nervous system: Common pathogenic and triggering factors

Frontiers in Neurology

Volumn 6, Issue MAR, 2015, Pages

  Koudriavtseva, Tatiana ^a   Renna, Rosaria ^a   Plantone, Domenico ^a   Mainero, Caterina ^b,c  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Acute disseminated encephalomyelitis; Antiphospholipid syndrome; Cerebral venous thrombosis; Multiple sclerosis; Neuromyelitis optica; Thrombosis

Indexed keywords

ACUTE DISSEMINATED ENCEPHALOMYELITIS; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CEREBRAL SINUS THROMBOSIS; DEMYELINATING DISEASE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE PREDISPOSITION; ENVIRONMENTAL FACTOR; HEREDITY; HUMAN; IMMUNOPATHOGENESIS; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PATHOPHYSIOLOGY; RISK ASSESSMENT; RISK FACTOR; THROMBOSIS;

EID: 84926482747     PISSN: None     EISSN: 16642295     Source Type: Journal    
DOI: 10.3389/fneur.2015.00063     Document Type: Article

References (48)

1. Karussis D. The diagnosis of multiple sclerosis and the various related demyelinating syndromes: a critical review. J Autoimmun (2014) 4(8-49):134-42. doi: 10.1016/j.jaut.2014.01.022
2. Miller DH, Weinshenker BG, Filippi M, Banwell BL, Cohen JA, Freedman MS, et al. Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler (2008) 14(9):1157-74. doi:10.1177/1352458508096878
3. Ferreira S, D'Cruz DP, Hughes GR. Multiple sclerosis, neuropsychiatric lupus and antiphospholipid syndrome: where do we stand? Rheumatology (Oxford) (2005) 44(4):434-42. doi:10.1093/rheumatology/keh532
4. Menge T, Hemmer B, Nessler S, Wiendl H, Neuhaus O, Hartung HP, et al. Acute disseminated encephalomyelitis: an update. Arch Neurol (2005) 62(11):1673-80. doi:10.1001/archneur.62.11.1673
5. Saposnik G, Barinagarrementeria F, Brown RD Jr, Bushnell CD, Cucchiara B, Cushman M, et al. Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2011) 42(4):1158-92. doi:10.1161/STR.0b013e31820a8364
6. Vandenberghe N, Debouverie M, Anxionnat R, Clavelou P, Bouly S, Weber M. Cerebral venous thrombosis in four patients with multiple sclerosis. Eur J Neurol (2003) 10(1):63-6. doi:10.1046/j.1468-1331.2003.00513.x
7. Maurelli M, Bergamaschi R, Candeloro E, Todeschini A, Micieli G. Cerebral venous thrombosis and demyelinating diseases: report of a case in a clinically isolated syndrome suggestive of multiple sclerosis onset and review of the literature. Mult Scler (2005) 11(2):242-4. doi:10.1191/1352458505ms1125cr
8. Kalanie H, Harandi AA, Alidaei S, Heidari D, Shahbeigi S, Ghorbani M. Venous thrombosis in multiple sclerosis patients after high-dose intravenous methylprednisolone: the preventive effect of enoxaparin. Thrombosis (2011) 2011:785459. doi:10.1155/2011/785459
9. Presicci A, Garofoli V, Simone M, Campa MG, Lamanna AL, Margari L. Cerebral venous thrombosis after lumbar puncture and intravenous high dose corticosteroids: a case report of a childhood multiple sclerosis. Brain Dev (2013) 35(6):602-5. doi:10.1016/j.braindev.2012.09.001
10. Stam J. Thrombosis of the cerebral veins and sinuses. N Engl J Med (2005) 352(17):1791-8. doi:10.1056/NEJMra042354
11. Bousser MG, Ferro JM. Cerebral venous thrombosis: an update. Lancet Neurol (2007) 6:162-70. doi:10.1016/S1474-4422(07)70029-7
12. Towbin A. The syndrome of latent cerebral venous thrombosis: its frequency and relation to age and congestive heart failure. Stroke (1973) 4(3):419-30. doi:10.1161/01.STR.4.3.419
13. Ferro JM, Canhao P, Stam J, Bousser MG, Barinagarrementeria F. ISCVT Investigators. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke (2004) 35:664-70. doi:10.1161/01.STR.0000117571.76197.26
14. Dale RC, Branson JA. Acute disseminated encephalomyelitis or multiple sclerosis: can the initial presentation help in establishing a correct diagnosis? Arch Dis Child (2005) 90(6):636-9. doi:10.1136/adc.2004.062935
15. Absoud M, Lim MJ, Chong WK, De Goede CG, Foster K, Gunny R, et al. Paediatric acquired demyelinating syndromes: incidence, clinical and magnetic resonance imaging features. Mult Scler (2013) 19(1):76-86. doi:10.1177/1352458512445944
16. Höllinger P, Sturzenegger M, Mathis J, Schroth G, Hess CW. Acute disseminated encephalomyelitis in adults: a reappraisal of clinical, CSF, EEG, and MRI findings. J Neurol (2002) 249(3):320-9. doi:10.1007/s004150200012
17. Zuccoli G, Panigrahy A, Sreedher G, Bailey A, Laney EJ IV, La Colla L, et al. Vasogenic edema characterizes pediatric acute disseminated encephalomyelitis. Neuroradiology (2014) 56(8):679-84. doi:10.1007/s00234-014-1379-2
18. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost (2006) 4(2):295-306. doi:10.1111/j.1538-7836.2006.01753.x
19. Harel M, Aron-Maor A, Sherer Y, Blank M, Shoenfeld Y. The infectious etiology of the antiphospholipid syndrome: links between infection and autoimmunity. Immunobiology (2005) 210(10):743-7. doi:10.1016/j.imbio.2005.10.004
20. Justo D, Finn T, Atzmony L, Guy N, Steinvil A. Thrombosis associated with acute cytomegalovirus infection: a meta-analysis. Eur J Intern Med (2011) 22(2):195-9. doi:10.1016/j.ejim.2010.11.006
21. Horstman LL, Jy W, Bidot CJ, Ahn YS, Kelley RE, Zivadinov R, et al. Antiphospholipid antibodies: paradigm in transition. J Neuroinflammation (2009) 20(6):3. doi:10.1186/1742-2094-6-3
22. Spadaro M, Amendolea MA, Mazzucconi MG, Fantozzi R, Di Lello R, Zangari P, et al. Autoimmunity in multiple sclerosis: study of a wide spectrum of autoantibodies. Mult Scler (1999) 5(2):121-5. doi:10.1191/135245899678847211
23. Bidot CJ, Horstman LL, Jy W, Jimenez JJ, Bidot C Jr, Ahn YS, et al. Clinical and neuroimaging correlates of antiphospholipid antibodies in multiple sclerosis: a preliminary study. BMC Neurol (2007) 7:36. doi:10.1186/1471-2377-7-36
24. Garg N, Zivadinov R, Ramanathan M, Vasiliu I, Locke J, Watts K, et al. Clinical and MRI correlates of autoreactive antibodies in multiple sclerosis patients. J Neuroimmunol (2007) 187(1-2):159-65. doi:10.1016/j.jneuroim.2007.04.008
25. Koudriavtseva T, D'Agosto G, Mandoj C, Sperduti I, Cordiali-Fei P. High frequency of antiphospholipid antibodies in relapse of multiple sclerosis: a possible indicator of inflammatory-thrombotic processes. Neurol Sci (2014) 35(11):1737-41. doi:10.1007/s10072-014-1823-4
26. Iong Y, He Y, Zheng Y, Chen M, Zhang B, Gao C. Serum anticardiolipin antibodies in patients with neuromyelitis optica spectrum disorder. J Neurol (2013) 260(12):3150-7. doi:10.1007/s00415-013-7128-3
27. Wu L, Huang D, Yang Y, Wu W. Combined screening for serum anti-nuclear and anti-aquaporin-4 antibodies improves diagnostic accuracy for distinguishing neuromyelitis optica from multiple sclerosis. Eur Neurol (2014) 72(1-2):103-8. doi:10.1159/000358218
28. Karussis D, Leker RR, Ashkenazi A, Abramsky O. A subgroup of multiple sclerosis patients with anticardiolipin antibodies and unusual clinical manifestations: do they represent a new nosological entity? Ann Neurol (1998) 44(4):629-34. doi:10.1002/ana.410440408
29. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology (2006) 66(10):1485-9. doi:10.1212/01.wnl.0000216139.44259.74
30. Koudriavtseva T, Plantone D, Renna R. Antiphospholipid antibodies: a possible biomarker of disease activity in multiple sclerosis and neuromyelitis optica spectrum disorders. J Neurol (2014) 261(10):2028-9. doi:10.1007/s00415-014-7506-5
31. Koga M, Takahashi T, Kawai M, Fujihara K, Kanda T. A serological analysis of viral and bacterial infections associated with neuromyelitis optica. J Neurol Sci (2011) 300(1-2):19-22. doi:10.1016/j.jns.2010.10.013
32. Long Y, Gao C, Qiu W, Hu X, Shu Y, Peng F, et al. Helicobacter pylori infection in neuromyelitis optica and multiple sclerosis. Neuroimmunomodulation (2013) 20(2):107-12. doi:10.1159/000345838
33. Masuda S, Mori M, Arai K, Uzawa A, Muto M, Uchida T, et al. Epstein-Barr virus persistence and reactivation in neuromyelitis optica. J Neurol Neurosurg Psychiatry (2014). doi:10.1136/jnnp-2014-308095
34. Zivadinov R, Ramanathan M, Ambrus J, Hussein S, Ramasamy DP, Dwyer MG, et al. Anti-phospholipid antibodies are associated with responseto interfereon-beta1a treatment in MS: results from a 3-year longitudinal study. Neurol Res (2012) 34(8):761-9. doi:10.1179/1743132812Y.0000000076
35. Christensen S, Farkas DK, Pedersen L, Miret M, Christiansen CF, Sørensen HT. Multiple sclerosis and risk of venous thromboembolism: a population-based cohort study. Neuroepidemiology (2012) 38(2):76-83. doi:10.1159/000335496
36. Vollmer T. The natural history of relapses in multiple sclerosis. J Neurol Sci (2007) 256(Suppl 1):S5-13. doi:10.1016/j.jns.2007.01.065
37. Austin AW, Patterson SM, von Känel R. Hemoconcentration and hemostasis during acute stress: interacting and independent effects. Ann Behav Med (2011) 42(2):153-73. doi:10.1007/s12160-011-9274-0
38. Mechelli R, Annibali V, Ristori G, Vittori D, Coarelli G, Salvetti M. Multiple sclerosis etiology: beyond genes and environment. Expert Rev Clin Immunol (2010) 6(3):481-90. doi:10.1586/eci.10.11
39. Owens GP, Gilden D, Burgoon MP, Yu X, Bennett JL. Viruses and multiple sclerosis. Neuroscientist (2011) 17(6):659-76. doi:10.1177/1073858411386615
40. Koudriavtseva T. Thrombotic processes in multiple sclerosis as manifestation of innate immune activation. Front Neurol (2014) 5:119. doi:10.3389/fneur.2014.00119
41. Akassoglou K, Adams RA, Bauer J, Mercado P, Tseveleki V, Lassmann H, et al. Fibrin depletion decreases inflammation and delays the onset of demyelination in a tumor necrosis factor transgenic mouse model for multiple sclerosis. Proc Natl Acad Sci U S A (2004) 101:6698-703. doi:10.1073/pnas.0303859101
42. Davalos D, Ryu JK, Merlini M, Baeten KM, Le Moan N, Petersen MA, et al. Fibrinogen-induced perivascular microglial clustering is required for the development of axonal damage in neuroinflammation. Nat Commun (2012) 3:1227. doi:10.1038/ncomms2230
43. Chapman J. Coagulation in inflammatory diseases of the central nervous system. Semin Thromb Hemost (2013) 39(8):876-80. doi:10.1055/s-0033-1357482
44. Nieswandt B, Kleinschnitz C, Stoll G. Ischaemic stroke: a thrombo-inflammatory disease? J Physiol (2011) 1(589):4115-23. doi:10.1113/jphysiol.2011.212886
45. Magnus T, Wiendl H, Kleinschnitz C. Immune mechanisms of stroke. Curr Opin Neurol (2012) 25(3):334-40. doi:10.1097/WCO.0b013e328352ede6
46. Göb E, Reymann S, Langhauser F, Schuhmann MK, Kraft P, Thielmann I, et al. Blocking of plasma kallikrein ameliorates stroke by reducing thromboinflammation. Ann Neurol (2015). doi:10.1002/ana.24380
47. Albert-Weissenberger C, Mencl S, Hopp S, Kleinschnitz C, Sirén AL. Role of the kallikrein-kinin system in traumatic brain injury. Front Cell Neurosci (2014) 8:345. doi:10.3389/fncel.2014.00345
48. Esmon CT, Xu J, Lupu F. Innate immunity and coagulation. J Thromb Haemost (2011) 9(Suppl 1):182-8. doi:10.1111/j.1538-7836.2011.04323.x